Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide s.c. in Cushing's Disease (SEASCAPE)
NCT01582061Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Jan 2017
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label trial of pasireotide LAR in Cushing's disease (CD) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE). Started Aug 2011; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT01582061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582061.